Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies

類似資料

• Riociguat for pulmonary arterial hypertension associated with congenital heart disease
  著者:: Rosenkranz, Stephan, 等
  出版事項: (2015)
• Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
  著者:: Cartin-Ceba, Rodrigo, 等
  出版事項: (2018)
• Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment
  著者:: Saleh, Soundos, 等
  出版事項: (2016)
• Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
  著者:: Ghofrani, Hossein A, 等
  出版事項: (2009)
• Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  著者:: Frey, Reiner, 等
  出版事項: (2016)